论文部分内容阅读
近10年来我们对局限期不能手术的小细胞肺癌开展了综合治疗研究。对1975-1981年间的157例应用放疗和联合化疗COPP方案(环磷酰胺、长春新碱、甲基苄肼、强的松)和BCOMP方案(卡氮芥、环磷酰胺、长春新碱、氨甲喋呤、强的松)及中药治疗的病人进行了随访。近期有效率为79％(完全缓解61,部分缓解63,无效33例),1、3、5年生存率CR病人为49％、21％和16％;PR病人为36％、9％和2％。与历史对照和同期收治、但因故未完成综合治疗计划的病人对比,本组生存率较高。
In the past 10 years, we have carried out comprehensive treatment research on small cell lung cancer that is inoperable for a limited period of time. 157 cases of COPD regimens (cyclophosphamide, vincristine, procarbazine, prednisone) and BCOMP regimens (radiocarbamide, cyclophosphamide, vincristine, methotrexate) for radiotherapy and combination chemotherapy from 1975 to 1981 , prednisone) and Chinese medicine patients were followed up. The effective rate in the near future was 79% (complete remission 61, partial remission 63, invalid 33 cases). The 1-, 3-, and 5-year survival rates of CR patients were 49%, 21%, and 16%; PR patients were 36%, 9%, and 2 %. Compared with patients who had historically been compared and treated at the same time, but had not completed the comprehensive treatment plan for some reason, the survival rate was higher in this group.